- Home
- FRD vs PLX Comparison
FRD vs PLX Comparison
Compare FRD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- PLX
- Stock Information
- Founded
- FRD 1965
- PLX 1993
- Country
- FRD United States
- PLX United States
- Employees
- FRD N/A
- PLX N/A
- Industry
- FRD Steel/Iron Ore
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FRD Industrials
- PLX Health Care
- Exchange
- FRD Nasdaq
- PLX Nasdaq
- Market Cap
- FRD 114.4M
- PLX 122.6M
- IPO Year
- FRD N/A
- PLX 1998
- Fundamental
- Price
- FRD $16.50
- PLX $1.52
- Analyst Decision
- FRD
- PLX Strong Buy
- Analyst Count
- FRD 0
- PLX 1
- Target Price
- FRD N/A
- PLX $15.00
- AVG Volume (30 Days)
- FRD 59.9K
- PLX 1.2M
- Earning Date
- FRD 06-12-2025
- PLX 08-13-2025
- Dividend Yield
- FRD 0.97%
- PLX N/A
- EPS Growth
- FRD N/A
- PLX N/A
- EPS
- FRD 0.87
- PLX 0.05
- Revenue
- FRD $444,600,000.00
- PLX $59,764,000.00
- Revenue This Year
- FRD N/A
- PLX $65.02
- Revenue Next Year
- FRD N/A
- PLX $57.34
- P/E Ratio
- FRD $18.93
- PLX $31.46
- Revenue Growth
- FRD N/A
- PLX 0.18
- 52 Week Low
- FRD $12.24
- PLX $0.82
- 52 Week High
- FRD $19.12
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- FRD 50.72
- PLX 45.63
- Support Level
- FRD $15.65
- PLX $1.32
- Resistance Level
- FRD $16.75
- PLX $1.67
- Average True Range (ATR)
- FRD 0.60
- PLX 0.11
- MACD
- FRD -0.02
- PLX 0.04
- Stochastic Oscillator
- FRD 52.16
- PLX 55.71
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.